BioMed Research International / 2016 / Article / Tab 1

Research Article

Prognostic Relevance of Nonsustained Ventricular Tachycardia in Patients with Pulmonary Hypertension

Table 1

Baseline characteristics.

Patients without nsVT Patients with nsVT Significance
p

Diagnosis (PH group 1/4)47/198/40.277
Age (years)60 ± 14.7
(Median: 60.5)
66.6 ± 12.4
(Median: 66)
0.112
Gender (female/male)50/168/40.277
PAH-specific medication (PDE5i/ERA/inh Prostanoid/CCB/Ima)28/7/0/5/25/2/0/1/0
Combination therapy (dual/triple)PDE5i + ERA = 15,PDE5i + ERA = 2,
PDE5i + inh Prostanoid = 3,PDE5i + inh Prostanoid = 2
PDE5i + ERA + inh Prostanoid = 4,
PDE5i + Ima = 2
Antiarrhythmic medication (BB/Digoxin)11/11/0
Angiotensin-converting enzyme
inhibitors
143
Coronary heart disease820.274
Arterial hypertension2870.238
Diabetes mellitus1240.261
Cardiac pacemaker01 (indication: bradyarrhythmia)

BB: beta blocker; CCB: calcium channel blocker; ERA: endothelin receptor antagonist; Ima: imatinib; inh Prostanoid: inhaled Prostanoid; n: number; PDE5i: phosphodiesterase-5 inhibitor; PH: pulmonary hypertension; nsVT: nonsustained ventricular tachycardia.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.